

Assay menu

Human

Analyte	Validation status	Measurement range	Sensitivity	Specificity (Cross-reactivity)
Insulin, normal range	Full validation FDAdraft 2013, EMA2012, CLSI	3–200 mU/L 0.13–8.70 µg/L	LOD: 1 mU/L LLOQ: 2.5 mU/L	Insulin aspart, 4% Insulin detemir, n.d. Insulin glargine, 24% Insulin glulisine, n.d. Insulin lispro, n.d.
Insulin, low range	Fit for purpose	0.15–20 mU/L 0.0065–0.87 µg/L	LOD: 0.15 mU/L	Insulin aspart, 3% Insulin detemir, n.d. Insulin glargine, 12% Insulin glulisine, n.d. Insulin lispro, n.d.
Insulin, Novolin	Fit for purpose	3–200 mU/L 0.13–8.70 µg/L	LLOQ: 3 mU/L	Insulin aspart, 4% Insulin detemir, n.d. Insulin glargine, 24% Insulin glulisine, n.d. Insulin lispro, n.d.
Insulin, highly specific	Full validation FDA2001, EMA2012	3–200 mU/L 0.13–8.70 µg/L	LLOQ: 3 mU/L	Insulin aspart, n.d. Insulin detemir, n.d. Insulin glargine, n.d. Insulin glargine M1, n.d. Insulin glargine M2, n.d. Insulin glulisine, n.d. Insulin lispro, n.d.
Insulin Lispro	Full validation FDA2018, EMA2012	1–500 mU/L 6–3000 pmol/L	LLOQ 1 mU/L ULOQ 500 mU/L	Insulin, human, n.d. Insulin, porcine, n.d. Insulin aspart, n.d. Insulin detemir, n.d. Insulin glargine, n.d. Insulin glargine M1, n.d. Insulin glargine M2, n.d. Insulin glulisine, n.d.
Total Insulin	Fit for purpose	3–100 mU/L 0.13–4.35 µg/L	LOD: 2 mU/L	Measures a broad range of insulin analogs and mammalian insulins, ie. "total insulin".
Insulin Glargine	Full validation FDA2001, EMA2012	5–200 mU/L	LLOQ: 5 mU/L	Total insulin assay, calibrated against glargine.
C-peptide, normal range	Full validation FDAdraft 2013, EMA2012, CLSI	100–4000 pmol/L 0.302–12.1 µg/L	LOD: 25 pmol/L LLOQ: 100 pmol/L	Insulin, human, n.d. Insulin, canine, n.d. Proinsulin, human 2%
C-peptide, low range	Full validation FDAdraft 2013, EMA2012, CLSI	5–280 pmol/L 0.015–0.846 µg/L	LOD: 2.5 pmol/L LLOQ: 5 pmol/L	Insulin, human, n.d. Insulin, canine, n.d. Proinsulin, human 5%
Glicentin	Fit for purpose	3–300 pmol/L 24–2400 pg/mL	LOD: 3 pmol/L	Glicentin, mouse, n.d. Glicentin, rat, 0.9% GLP-1, n.d. GLP-2, n.d. Glucagon, n.d. Mini-glucagon, n.d. Oxyntomodulin, n.d.
Glucagon	Full validation FDAdraft 2013, EMA2012, CLSI	1.5–130 pmol/L 5–453 pg/mL	LOD: 1.2 pmol/L LLOQ: 1.7 pmol/L	Glicentin, 0.8% GLP-1, <0.3% GLP-2, <0.3% GRPP, <0.0005% Mini-glucagon, <0.1% Oxyntomodulin, 4.4% Glucagen (recombinant glucagon for injection) 100%

Assay menu

Human

Analyte	Validation status	Measurement range	Sensitivity	Specificity (Cross-reactivity)
Leptin	Fit for purpose	0.1–5.0 ng/mL	LOD: 0.05 ng/mL	CNTF, n.d. G-CSF, n.d. IL-6, n.d. IL-11, n.d. IL-12, n.d. LIF, n.d. Leptin, mouse, n.d. Leptin, ovine, 0.003% Leptin, rat, 0.02% Oncostatin M, n.d.
Lp (a)	Fit for purpose	0.3–5.0 U/L	LOD: 0.07 U/L	
MPO	Fit for purpose	4–200 µg/L	LOD: 3 µg/L	
Oxidized LDL	Fit for purpose	1.4–21.3 mU/L (9.2–140 U/L when multiplied with dilution factor)	LOD: < 1 mU/L	Specific for human oxidized LDL.
Proinsulin	Fit for purpose	3.3–130 pmol/L	LOD: 1.7 pmol/L	C-peptide, <0.06% Insulin, <0.03% Proinsulin (Des 31–32), 95% Proinsulin (Split 32–33), 95% Proinsulin (Des 64–65), 84% Proinsulin (Split 65–66), 90% Proinsulin I, mouse 3% Proinsulin II, mouse 16% Proinsulin, porcine 4% Proinsulin I, rat 13% Proinsulin II, rat 10%
Total GLP-1	Full validation FDAdraft 2013, EMA2012, CLSI	0.9–940 pmol/L	LOD: 0.38 pmol/L LLOQ: 1 pmol/L	GIP, n.d. Glicentin, n.d. GLP-1 (1–36) amide 88% GLP-1 (7–36) amide 93% GLP-1 (9–36) amide 100% GLP-1 (1–37) n.d. GLP-1 (7–37) n.d. GLP-2, n.d. Glucagon, n.d. Oxyntomodulin, n.d. MPGF, n.d. Liraglutide, n.d. Exenatide, n.d. Lixisenatide, n.d. Dulaglutide, 0.07%
Total GIP	Fit for purpose	2.7–1000 pmol/L	LLOQ: 50 pg/mL	GLP-1, n.d. GLP-2, n.d. Glucagon, n.d. Oxyntomodulin, n.d.
FGF-1 acidic	Fit for purpose	150–2000 pg/mL	LLOQ: 150 pg/mL	